404 related articles for article (PubMed ID: 31673419)
1. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Strand V; Mysler E; Moots RJ; Wallenstein GV; DeMasi R; Gruben D; Soma K; Iikuni N; Smolen JS; Fleischmann R
RMD Open; 2019; 5(2):e001040. PubMed ID: 31673419
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
Rheumatology (Oxford); 2016 Jun; 55(6):1031-41. PubMed ID: 26929445
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
[No Abstract] [Full Text] [Related]
6. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Strand V; Burmester GR; Zerbini CA; Mebus CA; Zwillich SH; Gruben D; Wallenstein GV
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):475-83. PubMed ID: 25186034
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
8. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
[TBL] [Abstract][Full Text] [Related]
9. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
10. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.
Strand V; Lee EB; Fleischmann R; Alten RE; Koncz T; Zwillich SH; Gruben D; Wilkinson B; Krishnaswami S; Wallenstein G
RMD Open; 2016; 2(2):e000308. PubMed ID: 27752357
[TBL] [Abstract][Full Text] [Related]
12. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
14. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Strand V; van der Heijde D; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
Clin Exp Rheumatol; 2020; 38(5):848-857. PubMed ID: 31858963
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
18. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
[TBL] [Abstract][Full Text] [Related]
19. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
